Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire•10/11/2026•16:03 ET
0
Key Highlights
- ➤52-week oHCM data showed pVO2 improvement of 2.7 mL/kg/min from OLE baseline
- ➤90% of patients reached Valsalva LVOT-G below 30 mmHg during 52 weeks
- ➤LIONHEART-HCM Phase 3 enrolling; interim LVOT gradient analysis expected second half of 2027
- ➤Cash, cash equivalents and investments reached $503.5 million; runway expected into 2029
- ➤Third-quarter net loss $26.5 million, or $0.51 per share, versus $59.1 million in 2025
Expert Statements
Travis Murdoch, President and Chief Executive Officer of Braveheart Bio
“BHB-1893 continues to show a consistent, potentially differentiated profile across multiple clinical studies and our mechanistic work.”
Travis Murdoch, President and Chief Executive Officer of Braveheart Bio
“The 52-week data presented at AHA showed rapid, deep responses that continued to improve over time, including meaningful improvements in pVO2 and KCCQ-CSS, and evidence supporting a highly simplified dosing regimen.”
Travis Murdoch, President and Chief Executive Officer of Braveheart Bio
“These results inform our updated development strategy, including TRUEHEART-HCM, which will evaluate a fixed dose in oHCM on top of standard of care.”
Travis Murdoch, President and Chief Executive Officer of Braveheart Bio
“With LIONHEART-HCM enrolling, NOBLEHEART-HCM on track to initiate in the first half of 2027 and a strong balance sheet, we are focused on delivering a potential best-in-disease profile with a simple dosing paradigm for patients with HCM.”
52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893’s potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen
LIONHEART-HCM oHCM Phase 3 enrolling with interim analysis expected in second half of 2027; TRUEHEART-HCM fixed-dose oHCM Phase 2b and NOBLEHEART-HCM Phase 3 in nHCM on track to initiate in first half of 2027
Get started
Create a free account to read the full story.